Cingulate Inc (CING) - היקף יתרות מזומנים למניה

Cingulate Inc. maintains a positive image within the ADHD therapy niche, as evidenced by the cash per share data provided in GURU.Markets, where the value 1.55 captures the metric level. The business relies on a precision drug-release system to ensure a stable effect. High scalability potential is driven by intellectual property that enables the mass production of high-cost medications for the global market.
פילוחים אנליטיים של חברת Cingulate Inc (CING)

Cingulate Inc. is investing in unique CTR technology to develop ADHD medications with protection against generics. These R&D expenditures directly impact the cash balance per share. This metric measures the real value of cash reserves available to each shareholder. Sharp fluctuations in the current cash per share level signal secondary offerings or asset sales. Analyzing this chart allows for the immediate detection of investor equity dilution.